Retrospective analysis of 150 patients who had undergone sequential surgery for liver and lung metastasis from colorectal cancer identified prognostic factors for survival and cure. Median and 5-year overall survival were 76 months and 60% respectively. Twenty percent of patients were potential cured by this onco-surgical strategy. Background: Surgical resection is an established therapeutic strategy for colorectal cancer (CRC) metastasis. However, controversies exist when CRC liver and lung metastases (CLLMs) are found concomitantly or when recurrence develops after either liver or lung resection. No predictive score model is available to risk stratify these patients in preparation for surgery, and cure has not yet been reported. Patients and Methods: All consecutive patients who had undergone surgery for CLLMs at our institution during a 20-year period were reviewed. Our policy was to propose sequential surgery of both sites with perioperative chemotherapy, if the strategy was potentially curative. Overall survival, disease-free survival, and cure were evaluated. Results: Sequential resection was performed in 150 patients with CLLMs. The median number of liver and lung metastases resected was 3 and 1, respectively. The median follow-up period was 59 months (range, 7-274 months). The median, 5-year, and 10-year overall survival was 76 months, 60%, and 35% respectively. CRC that was metastatic at the initial diagnosis (P ¼ .012), a prelung resection carcinoembryonic antigen level > 100 ng/mL (P ¼ .014), a prelung resection cancer antigen 19-9 level > 37 U/mL (P ¼ .034), and an interval between liver and lung resection of < 24 months (P ¼ .024) were independent poor prognostic factors for survival. The 5-year survival was significantly different for patients with 2 and ! 3 risk factors (77.3% vs. 26.5%). Of 75 patients with ! 5 years of follow-up data available from the first metastasis resection, 15 (20%) with disease-free survival ! 5 years were considered cured. The use of targeted therapy was the only independent predictor of cure. Conclusion: Curative-intent surgery provides good long-term survival and offers a chance of cure in select patients. Patients with 2 risk factors are good candidates for sequential resection.
Introduction
One half of the patients undergoing radical resection of colorectal adenocarcinoma (CRC) will develop metastatic disease, with liver and lung being the most frequent sites of distant metastases.
1,2 Although chemotherapeutic regimens have evolved significantly during the past decade with the addition of biologic therapies, long-term survival and cure have been achieved only in patients who have undergone resection of all CRC liver metastases. [3] [4] [5] [6] [7] [8] [9] [10] With respect to CRC liver and lung metastases (CLLMs), various studies have reported survival after staged resection of both sites comparable to the survival observed after hepatic resection in patients without extrahepatic disease (EHD). [9] [10] [11] [12] However, no study has yet clearly established the best method to select patients for surgery, especially when metastases are found concomitantly in both organs or when patients who have undergone either liver or lung resection develop recurrence in the other organ. 5, 7, [13] [14] [15] The potential for cure in these patients is still questioned. We aimed to determine whether disease cure is possible in this cohort of patients who develop CLLMs. The additional objective was to identify the predictive factors for long-term survival and cure.
Patients and Methods

Study Cohort
All consecutive patients who had undergone sequential resection of CLLMs from January 1990 to December 2012 were identified from our prospective database and included in the present study. Patients with metastasis from neuroendocrine or noncolorectal primary tumors were excluded.
Preoperative Management
Once the radiologic diagnosis of liver and/or lung metastasis was confirmed in the tumor board by a multidisciplinary team consisting of surgeons, oncologists, and radiologists, our policy was to propose potentially curative resection of all metastatic sites with a combination of chemotherapy (CTx) with or without biologic agents. The response to CTx was evaluated every 2 to 3 months using the Response Evaluation Criteria In Solid Tumors and the following serum tumor markers: carcinoembryonic antigen (CEA; normal, 5 ng/mL) and carbohydrate antigen 19-9 (CA19-9; normal, 37 U/mL). 8 Surgery was considered when the overall strategy could eradicate both hepatic and EHD. Disease progression during CTx was considered a relative contraindication to curative surgery. Staged hepatic and EHD resection was performed, with CTx given during the interval between the 2 surgeries to prevent disease progression.
Hepatic Resection
The objective of hepatectomy was to resect all detectable lesions with tumor-free margins. When downsizing by CTx would not be sufficient to allow for curative resection owing to contact with a major vessel or bile duct, 3 specific techniques were practiced to increase resectability. Portal vein embolization was performed when the estimated remnant liver volume was < 30%. 16 For bilateral metastases, hemihepatectomy was combined with the radiofrequency ablation if a few contralateral, unresectable, deeply located lesions 3 cm in diameter were present. When multinodular bilobar metastases could neither be completely resected by a single procedure nor treated with hepatectomy combined with radiofrequency ablation, 2-stage hepatectomy was considered. 17 A liver-first strategy was used in certain cases of synchronous presentation when the CRC was not complicated, and the hepatic tumor burden was significant. 18 
Pulmonary Resection
Wedge resection, lobectomy, or pneumonectomy of all metastases with tumor-free margins was the objective of surgery.
Pulmonary resection was performed within 2 to 3 months of hepatectomy. 8 In the case of bilateral metastases, staged resection was usually performed. Intrathoracic lymph nodes were resected simultaneously when present.
Other Extrahepatic/Pulmonary Resection
The presence of limited synchronous other EHD was not a contraindication for either liver or lung resection when the strategy would be curative. If intra-abdominal EHD (nonregional lymph nodes, localized peritoneal carcinomatosis) was present at the initial liver resection, it was resected simultaneously. Extraabdominal EHD was resected after liver and lung resection. When other EHD was detected metachronously, resection was preformed to achieve cure.
Postoperative Management
Postoperative follow-up examinations were performed at 1 month and then every 4 to 6 months with physical examination, serum tumor marker determination, and imaging studies. Our policy was to offer CTx postoperatively for 6 to 8 cycles to decrease the risk of recurrence. In the case of local or distant recurrence, resection was performed if it could be curative. 19 
Definitions
Synchronous metastasis was that diagnosed before or within 3 months after resection of the primary colorectal tumor. 20 When the liver and lung metastases were diagnosed within 3 months of each other, they was considered simultaneous liver and lung metastases. 9 Overall survival (OS) was defined as the interval from the first resection of metastasis, either liver or lung, to the last follow-up visit. The disease-free interval from the last metastatic resection, liver, lung, and/or other EHD, to the last follow-up visit was defined as the disease-free survival (DFS). Patients with ! 5 years of DFS were considered potentially cured among the patients with ! 5 years of follow-up data available from the initial metastasis resection.
4,21
Statistical Analysis
Continuous variables are expressed as the median and range, and discrete variables are presented as counts and percentages. Survival analysis was performed using the Kaplan-Meier method, and survival curves were compared using the log-rank test. The Cox proportional hazard model was used to define the predictors of survival. Bootstrapped multivariate binary logistic regression analysis was performed to determine the predictors of cure. P < .05 was considered significant. SPSS software, version 20.0 (IBM Corp, Armonk, NY), was used for all statistical calculations.
Results
From January 1990 to December 2012, 1490 patients had undergone liver resection for CRC liver metastasis, and 156 of these patients had undergone sequential resection of CLLMs. Six patients whose data could not be retrieved were excluded from further analysis. The study cohort consisted of 150 patients (89 men, 61 women) with a median age of 56 years (range, 29-77 years). The patient demographics and tumor and treatment characteristics are summarized in Table 1 .
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Hepatic Resection Characteristics
The median number and size of the hepatic metastases resected was 3 (range, 1-17) and 35 mm (range, 7-186 mm), respectively. Synchronous liver metastasis was seen in 55% and bilobar localization was present in 51% of the patients. Preoperative CTx was administered to 75% of patients, and the regimens used were 5-fluoruracil and leucovorin (15%), 5-fluoruracil, leucovorin, and oxaliplatin (39%), 5-fluoruracil, leucovorin, and irinotecan (15%), and others, including intra-arterial CTx (6%). Of the patients receiving CTx, 15% received bevacizumab, cetuximab, or aflibercept along with CTx. In 46 patients (43%), the hepatic metastases were judged unresectable either because of vascular contact or insufficient remnant liver volume, and CTx was used to downstage the disease. The median number of CTx drugs used was 1 (range, 1-3), and the median number of cycles per patient was 8 (range, . A response was observed in 80% of these patients, with disease stabilization in 17% and progression in 3%. Classic CRC resection first, followed by liver resection was performed in 129 patients (86%), combined CRC and liver resection in 17 (11%), and a liver-first approach in 4 (3%). Anatomic liver resections (71%) included right extended hepatectomy including 2-stage hepatectomy (22%), right hepatectomy (15%), left extended hepatectomy (6%), left hepatectomy (5%), bisegmentectomy (11%), unisegmentectomy (11%), and central hepatectomy (1%), with 49% major hepatectomy. Nonanatomic partial hepatectomy was performed in 29%. CTx regimens similar to the ones used preoperatively were continued postoperatively in 89% patients. Intrahepatic recurrence was observed in 66% of the patients, with most of these patients (78%) undergoing repeat hepatectomy or radiofrequency ablation with curative intent. The median number of intrahepatic recurrences was 1 (range, 0-5). In total, the median number of hepatectomies performed per patient was 2 (range, 1-5).
Pulmonary Resection Characteristics
The median number and size of the pulmonary metastases resected was 1 (range, 1-5) and 15 mm (range, 4-60 mm), respectively. Synchronous presentation was seen 12%, and bilateral localization was present in 40% of patients. Simultaneous liver and lung metastases were observed in 31% of the patients. A combination of 5-fluoruracil and leucovorin with or without oxaliplatin or irinotecan was administered preoperatively in 65% of the patients, resulting disease stabilization in 54%, a partial response in 38%, and disease progression in 8%. In 25% of the patients, targeted therapy (bevacizumab, cetuximab, and panitumumab) was administered. Wedge resection (87%) and lobectomy, including staged bilateral resection (13%), were performed using either thoracoscopy or thoracotomy. Pulmonary recurrence was observed in 101 patients (67%), with 42% undergoing repeat curative intent surgery. The median number of pulmonary recurrences was 1 (range, 0-4). In total, the median number of pulmonary surgeries performed per patient was 1 (range, 1-5).
Resection of Extrahepatic/Pulmonary Metastases
Metastases in other localizations, such as nonregional abdominal lymph nodes (n ¼ 46), bone (n ¼ 23), peritoneum (n ¼ 15), brain (n ¼ 11), adrenal gland (n ¼ 9), and other sites (n ¼ 22), were observed in 57% of the patients. Approximately one third of these patients underwent potentially curative resection, such as lymphadenectomy (n ¼ 24), resection of localized peritoneal carcinomatosis (n ¼ 7), bone (n ¼ 6), and others (n ¼ 15).
OS and DFS
The 5-and 10-year OS probabilities were 60% and 35%, respectively. The median OS was 76 months (range, 8-277 months), with a median follow-up period of 59 months (range, 7-274 months). The 5-and 10-year DFS probabilities were 10% and 9%, respectively ( Figure 1 ). All characteristics listed in Table 1 were analyzed, and the variables with P < .05 on univariate analysis were entered into multivariate Cox regression analysis. Four independent prognostic factors for OS were identified: CRC metastatic at the initial diagnosis, prelung resection serum CEA > 100 ng/mL, prelung resection serum CA 19-9 > 37 U/mL, and interval between liver and lung resection < 24 months. No liver or chemotherapy factors were predictive of OS ( Table 2 ). The 5-year survival of patients with 0, 1, 2, 3, and 4 risk factors was 100%, 88.1%, 56.3%, 32.2%, and 0%, respectively. A cutoff of 2 risk factors was defined, and a significant difference was found in survival between patients with 2 and ! 3 risk factors ( Figure 2 ).
"Cured" and "Noncured" Patients
Of the 75 patients (50%) with a minimum follow-up period of 5 years from the first metastatic resection, 15 (20%) were considered cured and 60 (80%) were not cured. In the noncured group, 26 patients (43%) had died of CRC and 34 (57%) were alive with disease at their last follow-up visit. The cured and noncured patient characteristics are summarized in Table 3 . The 10-year OS for the cured and noncured patients was 93% and 12%, respectively, and in the cured patients, the OS remained 93% at 20 years (Supplemental Figure 1 ; available in the online version).
The cured patients (6 men, 9 women) had a median age of 57 years (range, 34-74 years). The median number of liver and lung metastases resected was 2 and 1, respectively. The types of liver Cure After Hepatic and Pulmonary Metastasis Resection resection were right extended hepatectomy (20%), right hepatectomy (7%), left hepatectomy (12%), bisegmentectomy (7%), unisegmentectomy (27%), and partial hepatectomy (27%). The pulmonary resections included 13 wedge resections (87%) and 2 lobectomies (13%). Intrahepatic and pulmonary recurrences were resected again in 2 and 3 patients, respectively. The median number of liver and lung resections was 1 each. Twelve patients (80%) were alive at the last follow-up visit, with a median DFS from last surgery of 9 years (range, 5-19 years). Among the probable preoperative factors predictive of cure (simultaneous liver and lung metastasis, the presence of extrahepatic/pulmonary metastasis, ! 2 CTx regimens used, and the use of targeted therapy), bootstrapped multivariate regression identified the use of targeted therapy as the only independent predictor of cure (Table 3) .
Discussion
Approximately 50% to 60% and 10% to 20% of patients who undergo curative resection of CRC will develop hepatic and pulmonary metastases, respectively. 1,2 Although EHD is a poor prognostic factor in patients undergoing hepatectomy, curative intent resection of both hepatic and EHD with perioperative chemotherapy is an established therapeutic strategy to improve OS. 8, 9, 14, 15 The 5-year OS after hepatectomy of liver-only metastasis and pulmonary metastasectomy for isolated lung metastasis was 40% to 50% and 30% to 70%, respectively. 14, 17, 20, 22, 23 The survival rates for patients who undergo curative resection of CLLMs were similar to, or even better than, those of patients undergoing either hepatic or pulmonary metastasectomy alone. Sequential surgery of CLLMs achieved a 5-year survival rate of 30% to 50%. 3, 9, 11, 12, 24 However, controversies still exist when metastases are found concomitantly in both organs or when patients who have undergone either liver or lung resection, develop recurrence in the other organ. 9, 25 With a better selection of patients, better survival could be obtained for these patients undergoing resection. 25, 26 In our series, the 5-and 10-year OS was comparable to that reported in recent studies. 5, 10 Thus, aggressive oncologic and surgical management in selected patients can achieve an excellent improvement in survival, with some patients alive > 15 years and enabled 20% of the resected patients to be potentially cured. In a recent multicenter study evaluating simultaneous liver and lung metastases, Andres et al 9 identified 7 independent predictors of survival. Similarly, Lida et al 14 reported tumor size, tumor number, prethoracotomy CEA level, lymph node involvement, and completeness of resection as independent predictors of surgical outcome after pulmonary metastasectomy for CRC metastasis. None of the previous studies proposed an effective and easy-to-use predictive model to identify patients who could benefit from sequential resection of CLLMs. We have proposed a cutoff of 2 risk factors to determine good candidates for surgical resection, because we found a significant difference in OS for patients with 2 (77%) and ! 3 risk factors (27%). The 4 poor prognostic factors for survival identified in the present study Cure After Hepatic and Pulmonary Metastasis Resection No liver metastasis-related factor was predictive of survival, suggesting that the distant-most metastasis, the lung in the present study, will determine the OS for patients who develop hepatic and pulmonary metastases from CRC. The role of hepatectomy-alone could be questioned when pulmonary metastasis cannot be subsequently resected.
14 Although the interval between liver and lung resection of < 24 months was a poor prognostic factor for OS, simultaneous liver and lung metastasis did not emerge as a negative factor and, rather, demonstrated a positive trend toward cure, highlighting the presence of a probable selection bias. The critical question that our study addressed was whether cure is possible for these patients. Although 6-and 10-year DFS have been proposed to indicate cure, we observed that DFS of ! 5 years was sufficient to determine the potential for cure in patients who were receiving regular postoperative follow-up care, consistent with our previous studies. 4, 5, [27] [28] [29] In a recent report about CRC liver metastasis, we also demonstrated that 5 years of DFS is adequate to define cure, with only 2 of 122 patients who were lost to follow-up developing recurrence after 5 years. 27 Because the DFS was estimated after resection of liver, lung, and/or other EHD metastases, when the patient was disease free at all sites, 20% DFS was observed at time 0. Although most of our patients developed recurrence and were alive with disease, cure was observed in 15 patients. The preoperative use of targeted therapy was the only independent predictor of cure. This reiterates fact that the tumor biology is the most important factor determining cure when similar treatment is offered and that the "test of time" and the response to CTx are the best methods for evaluating it clinically at present. 30 To the best of our knowledge, no previous study has reported cure after sequential resection of CLLMs. The present study is the largest single-center series of patients who underwent sequential resection for CLLMs (n ¼ 150), with the specificity that all patients were treated by the same oncology and surgical team using a similar treatment protocol, consisting of perioperative CTx, resection of all metastatic sites when the disease was responding to or stabilized by CTx, and repeat surgery in the case of new resectable disease recurrence. This consistency in management protocol was demonstrated by the finding that the period of treatment (first decade vs. second decade) was not a predictor of survival.
Study Limitations
A retrospective study conducted over a long period has inherent limitations such as heterogeneity of the study population and missing variables. Our study cohort was highly selected, representing only the "surgical" fraction of the total number of patients diagnosed with CLLMs. The prognostic value of specific CTx regimens could not fully explored in the present study, because most patients received perioperative CTx with similar response rates and owing to our policy of avoiding resection for patients with disease progression.
Conclusion
Cure is possible in well-selected patients who undergo curative intent sequential resection of CLLMs combined with perioperative CTx. Patients with 2 risk factors are good candidates for surgery. The preoperative use of targeted therapy is the only determinant of cure. With improvement in CTx and targeted therapy, surgery would considerably improve patient survival and their chance of cure.
Clinical Practice Points
Surgery combined with perioperative chemotherapy offers best long-term survival in patients with colorectal cancer metastasis. In the present study, 5 and 10-year survival achieved by this strategy were 60% and 35% respectively. Poor prognostic factors for survival were metastatic colorectal cancer at initial diagnosis; prelung resection CEA > 100 ng/mL; prelung resection CA19-9 > 37 U/mL and interval between liver-lung resections < 24 months. Patients with 2 risk factors have an excellent 5-year survival after sequential surgery and the role of surgery may be questioned in patients with ! 3 risk factors. Cure was possible in 20% of the patients who underwent sequential resection of hepatic and pulmonary metastases. Use of targeted therapy was the only independent predictor of cure. Aggressive onco-surgical management should be practiced to improve the chance of long-term survival and cure in patients with metastatic colorectal cancer.
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